Arcellx Signs a Development Evaluation and License Agreement with Pfenex for Advancing SparX Proteins
Shots:
- Pfenex to receive R&D funding along with $2.6M up to $18M as development- regulatory & commercial milestones and royalties on WW sales of products. Arcellx to get access to Pfenex expression technology platform to advance sparX proteins- activating- silencing & reprograming antigen- receptor complex T-cell based therapies
- Arcellx’s first sparX protein has completed its process development program leading to the initiation of the second sparX program- both focusing on hematologic malignancies
- The Pfenex expression technology platform is protein expression technology based on Pseudomonas fluorescens used to develop therapeutically equivalent vaccines- biologics and biosimilars which includes CRM197- PF708- PF743 & PF745
Click here to read full press release/ article | Ref: Globe Newswire | Image: Pfenex
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com